| Role of nucleophosmin in embryonic development and tumorigenesis S Grisendi, R Bernardi, M Rossi, K Cheng, L Khandker, K Manova, ... Nature 437 (7055), 147-153, 2005 | 709 | 2005 |
| Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity M Rossi, JW Young The Journal of Immunology 175 (3), 1373-1381, 2005 | 465 | 2005 |
| Indoleamine 2, 3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells DJ Chung, M Rossi, E Romano, J Ghith, J Yuan, DH Munn, JW Young Blood, The Journal of the American Society of Hematology 114 (3), 555-563, 2009 | 306 | 2009 |
| Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 256 | 2012 |
| Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 224 | 2013 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of Cellular Physiology, 2012 | 198 | 2012 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436, 2012 | 187 | 2012 |
| Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ... European journal of cancer 49 (3), 593-603, 2013 | 169 | 2013 |
| Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ... Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012 | 153 | 2012 |
| miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ... Oncotarget 6 (15), 12837, 2015 | 126 | 2015 |
| A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells T Calimeri, E Battista, F Conforti, P Neri, MT Di Martino, M Rossi, ... Leukemia 25 (4), 707-711, 2011 | 126 | 2011 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 120 | 2015 |
| miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells N Amodio, D Bellizzi, M Leotta, L Raimondi, L Biamonte, P D’Aquila, ... Cell Cycle 12 (23), 3650-3662, 2013 | 113 | 2013 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 111 | 2015 |
| Promises and challenges of MicroRNA-based treatment of multiple myeloma P Tagliaferri, M Rossi, M T Di Martino, N Amodio, E Leone, A Gulla, A Neri, ... Current cancer drug targets 12 (7), 838-846, 2012 | 103 | 2012 |
| In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells MT Di Martino, A Gullà, ME Gallo Cantafio, E Altomare, N Amodio, ... PloS one 9 (2), e89659, 2014 | 101 | 2014 |
| Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded … E Romano, M Rossi, G Ratzinger, MA de Cos, DJ Chung, KS Panageas, ... Clinical Cancer Research 17 (7), 1984-1997, 2011 | 88 | 2011 |
| In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor P Neri, P Tagliaferri, MT Di Martino, T Calimeri, N Amodio, A Bulotta, ... British journal of haematology 143 (4), 520-531, 2008 | 85 | 2008 |
| Molecular targets for the treatment of multiple myeloma M Rossi, M Teresa Di Martino, E Morelli, M Leotta, A Rizzo, A Grimaldi, ... Current cancer drug targets 12 (7), 757-767, 2012 | 73 | 2012 |
| A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients … MT Di Martino, M Arbitrio, PH Guzzi, E Leone, F Baudi, E Piro, T Prantera, ... British journal of haematology 154 (4), 529, 2011 | 72 | 2011 |
Pierfrancesco TassoneProfessor of Medical Oncology, Magna Graecia University, Catanzaro, ItalyVerified email at unicz.it
